- 1,393studies in the library match, of 29,380
- 231name it in the title
- 1995–2026years published
- 1,358peer-reviewed articles
The query: title or abstract mentions "MCI" or "mild cognitive impairment" AND "conversion"/"convert" or "progression"/"progress", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Mild cognitive impairment is a stage in which memory or thinking has declined more than expected for a person's age and education, but everyday life is still largely independent. It is not dementia, and it has more than one cause.
A conversion or progression rate is the share of people with MCI in a study who were later diagnosed with dementia, usually given per year or over the study's follow-up. Rates differ between studies because the people, the definition of MCI, the setting (memory clinic or general population) and the length of follow-up differ. Some people with MCI stay stable and some return to normal cognition, which is why the papers below give a range rather than one number.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 1,393 matched records are quoted; each links to its study page and from there to the paper.
“The clusterin (CLU) locus was an independent genetic risk factor for MCI to AD progression (CLU rs9331888: hazard ratio (HR)=1.187 (1.054-1.32); P=0.0035).”
“For conversion of mild cognitive impairment to dementia, one study showed a significant association with AF (OR 4.6, 95% CI 1.7 to 12.5).”
“In disease staging, while p-tau231 showed potential in detecting early amyloidosis, p-tau217_MS was superior for identifying advanced Tau-PET pathology (P-score = 0.91) and predicting MCI-to-dementia conversion (P-score = 0.82).”
“Besides, mABs were associated with a slower progression of cognitive decline on CDR-SOB (-0.30 (-0.60 to -0.001)) than AChEIs, although mABs and AChEIs did not differ across safety outcomes, including acceptability, tolerability, SAE, and all-cause mortality.”
“Lecanemab reduced the risk of progression to next stage of AD by 28 % on lecanemab as compared to the ADNI natural history cohort.”
“Compared to the unexposed group, the odds ratio (OR) for conversion to dementia in A+ MCI patients was 5.18 [95% CI 3.93; 6.81].”
“G. biloba also had no effect on the rate of progression to dementia in participants with MCI (HR, 1.13; 95% CI, 0.85-1.50; P = .39).”
“Results There were no differences between galantamine and placebo in 24-month conversion rates (Study 1: 22.9% [galantamine] vs 22.6% [placebo], p = 0.146; Study 2: 25.4% [galantamine] vs 31.2% [placebo], p = 0.619).”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 73 |
| Randomised controlled trial | 9 |
| Other clinical trial | 17 |
| Cohort or longitudinal study | 328 |
| Case-control study | 11 |
| Cross-sectional study | 66 |
| Other recorded design | 13 |
| No design recorded | 876 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 100 | |
| 2025 | 213 | |
| 2024 | 43 | |
| 2023 | 49 | |
| 2022 | 49 | |
| 2021 | 68 | |
| 2020 | 60 | |
| 2019 | 62 | |
| 2018 | 57 | |
| 2017 | 52 | |
| 2016 and earlier | 640 |
Other counts within the matched set
| Peer-reviewed articles | 1,358 |
| Marked open access in the record | 523 |
| Rated "high" evidence strength in alzhub's summary | 133 |
| Rated "moderate" evidence strength in alzhub's summary | 501 |
| Rated "low" evidence strength in alzhub's summary | 754 |
| No evidence-strength rating | 5 |
| Records stating a participant count | 653 |
| Median participants (those records) | 177 |
| Largest participant count | 508,107 |
Within the 1,393 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that also report an annual or per-year rate | 92 | the abstract also contains "per year", "annual" or "per annum" |
| …that also mention amyloid status | 382 | the abstract also contains "amyloid" |
| …that also mention reversion to normal cognition | 25 | the abstract also contains "revert" or "reversion" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment
- Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients
- Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies
- Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial
- Sex-specific brain reserve and progression from mild cognitive impairment to Alzheimer's disease dementia
- Comparing predictors of conversion and decline in mild cognitive impairment
- Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies
- Vascular risk factors, incidence of MCI, and rates of progression to dementia
- Predicting the progression of mild cognitive impairment using machine learning: A systematic, quantitative and critical review
Systematic reviews and meta-analyses in the set
73 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Alzheimer's Disease, Mild Cognitive Impairment and Mediterranean Diet. A Systematic Review and Dose-Response Meta-Analysis
- Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis
- Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis
- Effectiveness of Computerized Cognitive Training in Delaying Cognitive Function Decline in People With Mild Cognitive Impairment: Systematic Review and Meta-analysis
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
Newest matched studies
- Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment
- Tau-CTFP: A connectome-informed continuous-time first-passage model for forecasting the onset of regional tau PET abnormality
- Current gaps in downstream applications of fMRI foundation models: lessons learned from BrainLM & BrainHarmonix on Prevent-AD
- Plasma eMTBR-tau as a marker of clinical stage and progression across the Alzheimer’s disease continuum
- A digital biomarker of white-matter routing from diffusion MRI as an early biomarker of Alzheimer’s disease
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Neurology | 112 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 62 |
| Journal of Alzheimer's disease : JAD | 53 |
| Alzheimer's research & therapy | 38 |
| Brain : a journal of neurology | 33 |
Questions
- What is mild cognitive impairment?
- A measurable decline in memory or another thinking skill that is greater than expected for the person's age, while daily activities remain largely independent. It is a clinical stage, not a single disease: Alzheimer's is one cause among several.
- Does everyone with MCI go on to develop dementia?
- No. Follow-up studies find three groups: people who progress to dementia, people who stay stable, and people whose test scores return to the normal range. The share in each group depends on who was studied and for how long, which is why the papers quoted on this page report a range.
- How many studies on mci to dementia conversion rate does alzhub hold?
- 1,393 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "MCI" or "mild cognitive impairment" AND "conversion"/"convert" or "progression"/"progress""; 231 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 73 systematic review or meta-analysis, 9 randomised controlled trials, 17 other clinical trials, 328 cohort or longitudinal studys, 11 case-control studys, 66 cross-sectional studys; 876 record no design.
- What is the most recent study in the set?
- "Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment" (Research Square, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Neurology (112); Alzheimer's & dementia : the journal of the Alzheimer's Association (62); Journal of Alzheimer's disease : JAD (53), counted across the matched records.
Read on
- MCI to dementia conversion in the ADNI cohortalzhub's own analysis of one research cohort's progression figures.
- Early, middle and late stagesWhat changes at each stage, in plain language.
- Getting a diagnosisWhat the diagnostic process involves.